vs
Phillips Edison & Company, Inc.（PECO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Phillips Edison & Company, Inc.的1.1倍（$207.3M vs $190.7M），Phillips Edison & Company, Inc.净利率更高（17.4% vs -62.0%，领先79.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 7.0%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 8.7%）
联合爱迪生公司（通常简称Con Edison或ConEd）是总部位于纽约市的能源企业，为美国规模最大的投资者所有能源公司之一。截至2024年，该公司年营收约152.6亿美元，总资产超700亿美元，通过旗下子公司为客户提供多元化的能源相关产品与服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PECO vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $190.7M | $207.3M |
| 净利润 | $33.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 30.5% | -54.7% |
| 净利率 | 17.4% | -62.0% |
| 营收同比 | 7.0% | 25.9% |
| 净利润同比 | 15.1% | 3.5% |
| 每股收益（稀释后） | $0.24 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $190.7M | — | ||
| Q4 25 | $187.9M | $207.3M | ||
| Q3 25 | $182.7M | $159.9M | ||
| Q2 25 | $177.8M | $166.5M | ||
| Q1 25 | $178.3M | $139.3M | ||
| Q4 24 | $173.0M | $164.6M | ||
| Q3 24 | $165.5M | $139.5M | ||
| Q2 24 | $161.5M | $147.0M |
| Q1 26 | $33.2M | — | ||
| Q4 25 | $47.5M | $-128.6M | ||
| Q3 25 | $24.7M | $-180.4M | ||
| Q2 25 | $12.8M | $-115.0M | ||
| Q1 25 | $26.3M | $-151.1M | ||
| Q4 24 | $18.1M | $-133.2M | ||
| Q3 24 | $11.6M | $-133.5M | ||
| Q2 24 | $15.3M | $-131.6M |
| Q1 26 | 30.5% | — | ||
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% |
| Q1 26 | 17.4% | — | ||
| Q4 25 | 25.3% | -62.0% | ||
| Q3 25 | 13.5% | -112.8% | ||
| Q2 25 | 7.2% | -69.0% | ||
| Q1 25 | 14.8% | -108.5% | ||
| Q4 24 | 10.5% | -80.9% | ||
| Q3 24 | 7.0% | -95.7% | ||
| Q2 24 | 9.5% | -89.5% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.38 | $-1.28 | ||
| Q3 25 | $0.20 | $-1.81 | ||
| Q2 25 | $0.10 | $-1.17 | ||
| Q1 25 | $0.21 | $-1.57 | ||
| Q4 24 | $0.16 | $-1.34 | ||
| Q3 24 | $0.09 | $-1.40 | ||
| Q2 24 | $0.12 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.1M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $-80.0M |
| 总资产 | $5.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $3.1M | — | ||
| Q4 25 | $3.5M | $421.0M | ||
| Q3 25 | $4.1M | $202.5M | ||
| Q2 25 | $5.6M | $176.3M | ||
| Q1 25 | $5.5M | $127.1M | ||
| Q4 24 | $4.9M | $174.0M | ||
| Q3 24 | $6.4M | $150.6M | ||
| Q2 24 | $7.1M | $480.7M |
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.0B | — |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $-80.0M | ||
| Q3 25 | $2.3B | $9.2M | ||
| Q2 25 | $2.3B | $151.3M | ||
| Q1 25 | $2.3B | $144.2M | ||
| Q4 24 | $2.3B | $255.0M | ||
| Q3 24 | $2.2B | $346.8M | ||
| Q2 24 | $2.3B | $432.4M |
| Q1 26 | $5.4B | — | ||
| Q4 25 | $5.3B | $1.5B | ||
| Q3 25 | $5.3B | $1.2B | ||
| Q2 25 | $5.3B | $1.3B | ||
| Q1 25 | $5.2B | $1.3B | ||
| Q4 24 | $5.0B | $1.5B | ||
| Q3 24 | $5.0B | $1.5B | ||
| Q2 24 | $4.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.04× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | 0.99× | — | ||
| Q4 24 | 0.91× | — | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 0.90× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $55.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | 12.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.67× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $55.6M | — | ||
| Q4 25 | $348.1M | $-99.8M | ||
| Q3 25 | $95.4M | $-91.4M | ||
| Q2 25 | $96.1M | $-108.3M | ||
| Q1 25 | $60.5M | $-166.5M | ||
| Q4 24 | $334.7M | $-79.3M | ||
| Q3 24 | $109.1M | $-67.0M | ||
| Q2 24 | $78.5M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
| Q1 26 | 12.6% | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | 1.67× | — | ||
| Q4 25 | 7.33× | — | ||
| Q3 25 | 3.87× | — | ||
| Q2 25 | 7.52× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 18.45× | — | ||
| Q3 24 | 9.40× | — | ||
| Q2 24 | 5.14× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PECO
| Rental income | $186.3M | 98% |
| Fees and management income | $3.4M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
